已收盘 02-06 16:00:00 美东时间
+0.620
+6.78%
今日重点评级关注:HC Wainwright & Co.:维持Soleno Therapeutics"买入"评级,目标价从110美元升至120美元;富国银行:维持Soleno Therapeutics"超配"评级,目标价从106美元升至114美元
01-21 11:42
Needham analyst Matthew Calitri reiterates Allot (NASDAQ:ALLT) with a Buy and maintains $12.5 price target.
01-20 19:17
今日重点评级关注:HC Wainwright & Co.:维持Enlivex Therapeutics"买入"评级,目标价从7美元升至13美元;BTIG:维持Oruka Therapeutics"买入"评级,目标价从63美元升至73美元
01-13 10:18
Cantor Fitzgerald analyst Jonathan Ruykhaver initiates coverage on Allot (NASDAQ:ALLT) with a Overweight rating and announces Price Target of $15.
01-12 20:36
今日重点评级关注:Canaccord Genuity:维持Fractyl Health"买入"评级,目标价从6美元升至8美元;HC Wainwright & Co.:维持MediWound"买入"评级,目标价从31美元升至36美元
2025-11-24 11:23
Needham analyst Mike Cikos reiterates Allot (NASDAQ:ALLT) with a Buy and maintains $12.5 price target.
2025-11-21 18:42
Allot shares are trading higher after the company reported better-than-expected...
2025-11-20 22:07
Allot (NASDAQ:ALLT) narrows FY2025 sales outlook from $98.000 million-$120.000 million to $100.000 million-$103.000 million vs $99.802 million estimate.
2025-11-20 19:39
60% YoY SECaaS ARR growth with robust profitability; raising full year guidance HOD HASHARON, Israel, Nov. 20, 2025 /PRNewswire/ -- Allot Ltd. (NASDAQ: ALLT) (TASE: ALLT), a leading global p...
2025-11-20 19:30
Allot (NASDAQ:ALLT) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.04 by 143.9 percent. This is a 233.33 percent increase over earnings of $0.03 per share from the same
2025-11-20 19:22